CAS: 136941-85-0 - 2-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)ethyl tetrahydro-2H-pyran-2-ylmethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Fórmula:C30H31N3O10S
InChI:InChI=1/C30H31N3O10S/c1-18-25(29(35)42-15-13-32-28(34)23-11-3-4-12-24(23)44(32,39)40)27(20-8-7-9-21(16-20)33(37)38)26(19(2)31-18)30(36)43-17-22-10-5-6-14-41-22/h3-4,7-9,11-12,16,22,27,31H,5-6,10,13-15,17H2,1-2H3
| Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
|---|---|---|---|---|
 | PCA50941 REF: 3D-LFA94185CAS: 136941-85-0 | Min. 95% | A consultar | Vie 10 Ene 25 |
 | PCA50941 REF: TM-T13812CAS: 136941-85-0 | 98% | 904,00 €~2.329,00 € | Vie 17 Ene 25 |
PCA50941
CAS:136941-85-0
PCA50941 is a peptide that has been shown to be an activator of ion channels. …
Fórmula:
C30H31N3O10S
Pureza:
Min. 95%
Peso molecular:
625.6 g/mol
Ref: 3D-LFA94185
| 1mg | A consultar |
Entrega estimada en Estados Unidos, el Viernes 10 de Enero de 2025
PCA50941
CAS:136941-85-0
PCA50941 is a 1,4-dihydropyridine derivative, treatment for cardiovascular disease.
Fórmula:
C30H31N3O10S
Pureza:
98%
Forma y color:
Solid
Peso molecular:
625.65
Ref: TM-T13812
| 25mg | 1.410,00 € | ||
| 50mg | 1.845,00 € | ||
| 100mg | 2.329,00 € |
Entrega estimada en Estados Unidos, el Viernes 17 de Enero de 2025
